{
    "clinical_study": {
        "@rank": "109365", 
        "arm_group": [
            {
                "arm_group_label": "Control: patients without fatigue", 
                "description": "Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls"
            }, 
            {
                "arm_group_label": "Patients with fatighe", 
                "description": "Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue"
            }
        ], 
        "brief_summary": {
            "textblock": "Fatigue is common in cancer patients receiving adjuvant chemotherapy. To further understand\n      the mechanism of fatigue and search for potential biomarkers, we will conduct a prospective\n      study with breast cancer patients receiving adjuvant chemotherapy."
        }, 
        "brief_title": "Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Fatigue", 
            "Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Fatigue"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with breast cancer undergoing adjuvant systemic chemotherapy based on the use of\n      anthracyclines will be screened before the start of chemotherapy.\n\n      Patients whose scores on the brief fatigue inventory (BFI) increase after having received\n      the first cycle of chemotherapy will be considered as having manifested fatigue. The\n      patients whose fatigue won't worse  following the first cycle of chemotherapy will be used\n      as controls. We will collect blood samples of both groups before and 21 days after the start\n      of chemotherapy. We will analyze the following biomarkers: IL2, IL10, TNF and TGFB-1\n      measured by amplification reaction; FSH, LH, estradiol, DHEA, DHEAS and cortisol hormones\n      measured by chemiluminescent enzyme immunometric assay"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non metastatic breast cancer;\n\n          -  Patients undergoing adjuvant chemotherapy\n\n        Exclusion Criteria:\n\n          -  hypothyroidism;\n\n          -  Depression;\n\n          -  anemia;\n\n          -  heart disease or decompensated hypertension"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with stage I, II and III breast cancer undergoing adjuvant systemic chemotherapy\n        based on the use of anthracyclines will be screened before the start of their treatment."
            }
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02041364", 
            "org_study_id": "Biomarker fatigue ABC001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fatigue", 
            "Biomarkers", 
            "Breast Cancer"
        ], 
        "lastchanged_date": "January 18, 2014", 
        "location": {
            "contact": {
                "email": "felipemcruz@yahoo.com.br", 
                "last_name": "Felipe Cruz, PhD", 
                "phone": "551181388214"
            }, 
            "facility": {
                "address": {
                    "city": "Santo Andre", 
                    "country": "Brazil", 
                    "state": "Sao Paulo", 
                    "zip": "09030-310"
                }, 
                "name": "Cepho-Fmabc"
            }, 
            "investigator": {
                "last_name": "Felipe M Cruz, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_groups": "2", 
        "official_title": "Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer: Evaluation of Plasma and Lymphocyte Expression.", 
        "overall_contact": {
            "email": "felipemcruz@yahoo.com.br", 
            "last_name": "Felipe M Cruz, PhD", 
            "phone": "551144362094"
        }, 
        "overall_official": {
            "affiliation": "551134744249", 
            "last_name": "Felipe M Cruz, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This study examines potential biomarkers of fatigue induced by chemotherapy both in the plasma and mononuclear fraction of the peripheral blood of patients with breast cancer", 
            "measure": "Potential biomarkers related to chemotherapy induced fatigue", 
            "safety_issue": "No", 
            "time_frame": "21 days after the start of chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02041364"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Faculdade de Medicina do ABC", 
            "investigator_full_name": "Felipe Melo Cruz", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Faculdade de Medicina do ABC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Faculdade de Medicina do ABC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}